

**FEDERAL TRADE COMMISSION****Advisory Committee on Online Access and Security****AGENCY:** Federal Trade Commission.**ACTION:** Notice of meeting on March 31, 2000.

**SUMMARY:** Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. § 10(a)(2), and 16 CFR 16.9(a), notice is hereby given that the Federal Trade Commission Advisory Committee on Online Access and Security will hold a meeting on Friday, March 31, 2000, from 8:00 a.m. to 4:00 p.m. in Room 432, Federal Trade Commission, 600 Pennsylvania Avenue, N.W., Washington, DC 20580. The meeting is open to the public and will include a period for public comment. The purpose of the Advisory Committee is to provide advice and recommendations to the Commission regarding implementation of certain fair information practices by domestic commercial Web sites—specifically, providing online consumers reasonable access to personal information collected from and about them, and maintaining adequate security for that information. Interested parties may submit comments concerning any matter to be considered at the meeting by following the procedures described below.

**DATES:** The Advisory Committee will meet on Friday, March 31, 2000, from 8:00 a.m. to 4:00 p.m.

**ADDRESSES:** The meeting will take place in Room 432, Federal Trade Commission, 600 Pennsylvania Avenue, N.W., Washington, DC 20580.

**FOR FURTHER INFORMATION CONTACT:**

Allison Brown, Division of Financial Practices, Federal Trade Commission, 600 Pennsylvania Avenue, N.W., Mail Stop 4429, Washington, DC 20580, telephone (202) 326-3079, email [aibrown@ftc.gov](mailto:aibrown@ftc.gov).

**SUPPLEMENTARY INFORMATION:**

**Authority:** 15 U.S.C. § 41 *et seq.*; 5 U.S.C. App. §§ 1-15; 16 CFR Part 16.

The third meeting of the Federal Trade Commission Advisory Committee on Online Access and Security will be held on Friday, March 31, 2000, in Room 432, Federal Trade Commission, 600 Pennsylvania Avenue, N.W., Washington, DC from 8:00 a.m. to 4:00 p.m.

The Advisory Committee will continue to consider the costs and benefits, to both consumers and businesses, of implementing the fair information practices of access and security with respect to personal information collected for and about

consumers online. The Advisory Committee will also continue consideration of the parameters of reasonable access to personal information and adequate security and will present options for implementation of these information practices in a report to the Commission.

The tentative agenda for the third meeting is as follows:

1. Administrative matters
2. Discussion of option papers submitted by subgroups on issues relating to "reasonable access"
3. Discussion of option papers submitted by subgroup on issues relating to "adequate security"
4. Public Comment
5. Discussion of tasks and assignments

The meeting is open to the public.

**Submission of Documents**

Interested parties who wish to submit comments on the meeting agenda or questions for consideration by the Advisory Committee should send an original and two copies in advance of the meeting to the Secretary, Federal Trade Commission, Room H-159, 600 Pennsylvania Avenue, N.W., Washington, DC 20580. All comments and questions should be captioned "Advisory Committee on Online Access and Security—Comment, P004807." To enable prompt review and public access, paper submissions should be accompanied by a version on diskette in ASCII, WordPerfect (please specify version) or Microsoft Word (please specify version) format. Diskettes should be labeled with the name of the submitter, the Advisory Committee caption, and the name and version of the word processing program used to create the document.

Alternatively, comments or questions may be submitted to the following email address: [advisorycommittee@ftc.gov](mailto:advisorycommittee@ftc.gov); if submitted by email, only one copy of the comment or question is required. The email should contain the name of the submitter, the Advisory Committee caption, and, if a document is attached, the name and version of the word processing program used to create the document.

To ensure that comments are processed properly, individuals submitting comments should be sure to use the above addresses. All comments will be posted on the Advisory Committee's Web page at [www.ftc.gov/acoas](http://www.ftc.gov/acoas) as soon as reasonably possible, and likely within 5 business days of receipt.

By direction of the Commission.

**Donald S. Clark,**

*Secretary of the Commission.*

[FR Doc. 00-6497 Filed 3-15-00; 8:45 am]

**BILLING CODE 6750-01-M**

**GENERAL SERVICES ADMINISTRATION****Office of Communications, Standard and Optional Forms Management Office; Cancellation of a Standard Form**

**AGENCY:** General Services Administration.

**ACTION:** Notice.

**SUMMARY:** Because of low usage, the following Optional Form is cancelled:

OF 10, U.S. Government Memorandum.

**FOR FURTHER INFORMATION CONTACT:** Ms. Barbara Williams (202) 501-0581.

**DATES:** Effective March 16, 2000.

Dated: February 29, 2000.

**Barbara M. Williams,**

*Deputy Standard and Optional Forms Management Officer.*

[FR Doc. 00-6467 Filed 3-15-00; 8:45 am]

**BILLING CODE 6820-34-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Notice of Meeting of the Advisory Committee on Blood Safety and Availability**

**AGENCY:** Office of the Secretary.

**ACTION:** Notice of meeting.

The Advisory Committee on Blood Safety and Availability will meet on Tuesday, April 25, 2000, from 9 a.m. to 5 p.m. and on Wednesday, April 26, 2000 from 9 a.m. to 3 p.m. The meeting will take place at the Hyatt Regency Capitol Hill Hotel, 400 New Jersey Ave., NW., Washington, DC 20001. The meeting will be entirely open to the public.

On April 25 the Committee will consider how strategies to reduce errors and accidents in transfusion medicine can reconcile the right of the patient to know the consequences of any treatment received, the need of regulatory agencies for information necessary for them to fulfill their statutory oversight responsibilities, and the interest of society in perfecting mechanisms that identify and correct latent, life-threatening flaws in critical health care systems.

On April 26 the Committee will consider incremental reimbursement

policies for blood and blood products in response to the introduction of new safety measures.

Public comment will be solicited both days. Public comment will be limited to three minutes per speaker. Those who wish to have printed material distributed to Advisory Committee members should submit thirty (30) copies to the Executive Secretary prior to close of business April 10, 2000.

**FOR FURTHER INFORMATION CONTACT:**

Stephen D. Nightingale, M.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, Office of Public Health and Safety, 200 Independence Avenue SW., Rm 736E, Washington, DC 20201. Phone (202) 690-5560 FAX (202) 690-7560 e-mail stephendnightingale@osophs.dhhs.gov.

Dated: March 9, 2000.

**Stephen D. Nightingale,**

*Executive Secretary, Advisory Committee on Blood Safety and Availability.*

[FR Doc. 00-6430 Filed 3-15-00; 8:45 am]

**BILLING CODE 4160-17-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**[60Day-00-27]**

**Proposed Data Collections Submitted for Public Comment and Recommendations**

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Center for Disease Control and Prevention is providing opportunity for public comment on proposed data collection projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639-7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have

practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

**Proposed Project**

1. Workplace Exacerbation of Asthma—NEW—The National Institute of Occupational Safety and Health (NIOSH)—Work-related asthma is the most common lung disease seen in occupational health clinics in the United States based on data from the Association of Occupational and Environmental Clinics for 1991-1996. Work-related asthma includes both new onset asthma initiated by workplace exposures and preexisting asthma exacerbated by workplace environments, because in both types of cases repeated exposure to asthmatic agents can lead to chronic pulmonary impairment. Also, the 1985 American Thoracic Society statement "What Constitutes an Adverse Health Effect of Air Pollution" identified exacerbation of asthma as one of the serious effects of environmental air pollution. While anecdotal evidence suggests that as many as one-half of work-related asthma patients treated in occupational medicine clinics had pre-existing asthma that was exacerbated by workplace conditions, there is little data from studies in the United States to support this claim.

This study will investigate the frequency, causes, and consequences of workplace exacerbation of asthma (WEA). Given the diversity of workplace agents and processes associated with asthma, a population-based, rather than industry-based, study is needed to ascertain the full extent of the problem. This will be achieved by surveying adults with asthma. The Specific Aims

are: (1) To determine the frequency of workplace exacerbation of asthma. (2) To determine the circumstances at work associated with exacerbation of asthma. (3) To determine the social and economic costs associated with workplace exacerbation of asthma. (4) To determine the sensitivity and specificity of self-reported workplace exacerbation of asthma. (5) To determine whether workplace exacerbation of asthma contributes to progression of disease. The design is a prospective cohort study with a nested validation study. A questionnaire will be completed in the baseline study to address Specific Aims 1-3. Also, patient care records will be used to ascertain cost of asthma care for each participant (Specific Aim 3). A subset of employed subjects with and without workplace exacerbation will be requested to conduct serial spirometry, and the findings will serve as the "gold standard" to determine the sensitivity and specificity of a self-report of workplace exacerbation of asthma (Specific Aim 4). All subjects from the baseline study will be asked to complete a follow-up questionnaire approximately two years later to investigate whether workplace exacerbation at baseline predicts an increase in asthma severity (Specific Aim 5).

The data collected in this study will be used to further current understanding of the frequency of workplace-exacerbated asthma, the social and economic impacts of this problem, and the implication of a report of WEA for subsequent asthma severity. This information can be used to prioritize resources for addressing this problem. The data collected in this study will also identify which jobs and exposures are likely to exacerbate existing asthma, thus providing guidance on where to focus preventive efforts. The data collected in this study on the validity of a self-report of WEA will be useful to both clinicians and researchers who attempt to treat or study individuals with this problem.

Based on an average hourly wage of \$15 among all occupational groups combined, the total cost to respondents is \$37,500.

Respondents (adults with asthma)	Number of respondents	Number of responses/respondent	Avg. burden per response (in hrs.)	Total burden (in hrs.)
Baseline Study .....	800	1	0.5	400
Validation Study .....	240	1	7.5	1800
Follow-up Study .....	600	1	0.5	300
Total .....	.....	.....	.....	2500